Todd Berard Sells 8,902 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 8,902 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $201,719.32. Following the sale, the chief marketing officer now owns 135,956 shares in the company, valued at $3,080,762.96. The trade was a 6.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Todd Berard also recently made the following trade(s):

• On Tuesday, March 11th, Todd Berard sold 1,577 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total value of $39,425.00.
• On Monday, March 3rd, Todd Berard sold 424 shares of BioLife Solutions stock. The shares were sold at an average price of $25.46, for a total transaction of $10,795.04.
• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total transaction of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $9,267.86.

BioLife Solutions Price Performance

Shares of BLFS traded down $1.34 during trading hours on Thursday, reaching $22.44. 591,144 shares of the stock traded hands, compared to its average volume of 358,590. The company has a market cap of $1.05 billion, a P/E ratio of -21.17 and a beta of 2.04. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average price is $26.11 and its two-hundred day moving average price is $25.54. BioLife Solutions, Inc. has a 52-week low of $14.84 and a 52-week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The firm had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same quarter in the prior year, the company posted ($0.21) earnings per share. On average, analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BLFS has been the topic of a number of analyst reports. StockNews.com cut shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Monday. KeyCorp boosted their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Northland Securities lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. HC Wainwright boosted their target price on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Finally, Benchmark reiterated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.86.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp increased its holdings in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after acquiring an additional 95,788 shares during the last quarter. Geode Capital Management LLC grew its holdings in BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after buying an additional 18,473 shares in the last quarter. Barclays PLC increased its stake in BioLife Solutions by 20.1% in the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock worth $1,613,000 after acquiring an additional 10,803 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of BioLife Solutions by 40.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock valued at $487,000 after acquiring an additional 5,638 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in BioLife Solutions in the fourth quarter worth $638,000. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.